Cargando…
Targeting angiogenesis for liver cancer: Past, present, and future
Liver cancer, mostly hepatocellular carcinoma (HCC), is the second leading cause of cancer mortality globally. Most patients were diagnosed at an advanced stage, and systemic therapy is the standard of care. All the approved systemic therapies for HCC are molecular targeted therapies with anti-angio...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chongqing Medical University
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452391/ https://www.ncbi.nlm.nih.gov/pubmed/32884987 http://dx.doi.org/10.1016/j.gendis.2020.03.010 |
_version_ | 1783575150364459008 |
---|---|
author | Zhu, Xiao-Dong Tang, Zhao-You Sun, Hui-Chuan |
author_facet | Zhu, Xiao-Dong Tang, Zhao-You Sun, Hui-Chuan |
author_sort | Zhu, Xiao-Dong |
collection | PubMed |
description | Liver cancer, mostly hepatocellular carcinoma (HCC), is the second leading cause of cancer mortality globally. Most patients were diagnosed at an advanced stage, and systemic therapy is the standard of care. All the approved systemic therapies for HCC are molecular targeted therapies with anti-angiogenic effects targeting the vascular endothelial growth factor signaling pathway. Sorafenib and lenvatinib are the first-line treatment, and regorafenib, ramucirumab, and cabozantinib are second-line treatment options. Although anti-PD-1 antibodies, including nivolumab and pembrolizumab, demonstrated promising anti-tumor effects as monotherapy for advanced HCC in phase II clinical trials, both failed in phase III studies. Anti-angiogenic treatment remains the backbone of systemic therapy for HCC. In this review, we summarized the approved anti-angiogenic medicines and discussed the potential strategies to improve the efficacy of anti-angiogenic therapy, including combination therapy with other treatments, and discussed the approaches to overcome the drawbacks of anti-angiogenic therapies. |
format | Online Article Text |
id | pubmed-7452391 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Chongqing Medical University |
record_format | MEDLINE/PubMed |
spelling | pubmed-74523912020-09-02 Targeting angiogenesis for liver cancer: Past, present, and future Zhu, Xiao-Dong Tang, Zhao-You Sun, Hui-Chuan Genes Dis Article Liver cancer, mostly hepatocellular carcinoma (HCC), is the second leading cause of cancer mortality globally. Most patients were diagnosed at an advanced stage, and systemic therapy is the standard of care. All the approved systemic therapies for HCC are molecular targeted therapies with anti-angiogenic effects targeting the vascular endothelial growth factor signaling pathway. Sorafenib and lenvatinib are the first-line treatment, and regorafenib, ramucirumab, and cabozantinib are second-line treatment options. Although anti-PD-1 antibodies, including nivolumab and pembrolizumab, demonstrated promising anti-tumor effects as monotherapy for advanced HCC in phase II clinical trials, both failed in phase III studies. Anti-angiogenic treatment remains the backbone of systemic therapy for HCC. In this review, we summarized the approved anti-angiogenic medicines and discussed the potential strategies to improve the efficacy of anti-angiogenic therapy, including combination therapy with other treatments, and discussed the approaches to overcome the drawbacks of anti-angiogenic therapies. Chongqing Medical University 2020-04-07 /pmc/articles/PMC7452391/ /pubmed/32884987 http://dx.doi.org/10.1016/j.gendis.2020.03.010 Text en © 2020 Chongqing Medical University. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Zhu, Xiao-Dong Tang, Zhao-You Sun, Hui-Chuan Targeting angiogenesis for liver cancer: Past, present, and future |
title | Targeting angiogenesis for liver cancer: Past, present, and future |
title_full | Targeting angiogenesis for liver cancer: Past, present, and future |
title_fullStr | Targeting angiogenesis for liver cancer: Past, present, and future |
title_full_unstemmed | Targeting angiogenesis for liver cancer: Past, present, and future |
title_short | Targeting angiogenesis for liver cancer: Past, present, and future |
title_sort | targeting angiogenesis for liver cancer: past, present, and future |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452391/ https://www.ncbi.nlm.nih.gov/pubmed/32884987 http://dx.doi.org/10.1016/j.gendis.2020.03.010 |
work_keys_str_mv | AT zhuxiaodong targetingangiogenesisforlivercancerpastpresentandfuture AT tangzhaoyou targetingangiogenesisforlivercancerpastpresentandfuture AT sunhuichuan targetingangiogenesisforlivercancerpastpresentandfuture |